ENDO Online 2020

Thank you to our supporters

The Endocrine Society is proud to partner with peers and industry to advance excellence and promote scientific discovery, medical practice, and human health.

Endo Online 2020 Supporters as of June 1, 2020.

Amarin
Amryt Pharma
Eisai
Horizon
Immunovant
Ipsen
Medtronic
Radius
Strongbridge Biopharma
The Leona M. and Harry B. Helmsley Charitable Trust
THANK YOU TO OUR PARTNER SOCIETIES

WHO HAVE OFFERED THEIR ENDORSEMENT AND HELPED TO PROMOTE THIS OPPORTUNITY TO THE ENDOCRINE COMMUNITY.

# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>GENERAL INFORMATION</td>
</tr>
<tr>
<td>4</td>
<td>LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 8–12</td>
</tr>
<tr>
<td>9</td>
<td>BASIC SCIENCE DAY: JUNE 8</td>
</tr>
<tr>
<td>13</td>
<td>LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 15–19</td>
</tr>
<tr>
<td>15</td>
<td>ON-DEMAND SESSIONS</td>
</tr>
<tr>
<td>19</td>
<td>25TH ANNIVERSARY OF DIVERSITY AND INCLUSION</td>
</tr>
<tr>
<td>20</td>
<td>AWARD AND LAUREATE RECIPIENTS</td>
</tr>
<tr>
<td>21</td>
<td>PRODUCT THEATERS AND EXHIBIT HALL VIEWING</td>
</tr>
</tbody>
</table>
We are excited to offer ENDO Online 2020, our largest-ever virtual meeting for endocrine researchers and clinicians. This complimentary event will take place June 8-22, and will feature a comprehensive mixture of on-demand and live programming, offering attendees the opportunity to learn about the latest developments in hormone science and medicine from renowned investigators, expert clinicians, and educators from all over the world.

ENDO Online 2020 includes:
- an easy-to-navigate online Conference Center;
- on-demand sessions focused on a variety of clinical topics, including pituitary, diabetes, and more;
- live programming dedicated to basic science;
- availability to earn Continuing Medical Education credits and Maintenance of Certification points;
- programming for early career professionals; and
- a digital exhibit hall where participants can access resources and chat with exhibitors about the latest science and technology.

CONTINUING MEDICAL EDUCATION AND MAINTENANCE OF CERTIFICATION
The Endocrine Society designates this educational activity for a maximum of 23.75 AMA PRA Category 1 Credit(s)™ for ENDO Online 2020. Physicians should claim only the credit commensurate with extent of their participation in the activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

In addition, ENDO Online 2020 credit, each ancillary symposium will provide 1.5 AMA PRA Category 1 Credits(s)™ and the 2020 Endocrine Fellows Series: Type 1 Diabetes Care and Management course will provide 10.25 AMA PRA Category 1 Credits(s)™.

ENDO 2021
ENDO is the place where leading experts, researchers, and the most respected clinicians in the field come together to share the latest findings in hormone science and discuss breakthroughs in clinical care. We are excited to host ENDO 2021 at the San Diego Convention Center in San Diego, CA, USA, on March 20–23, 2021. For additional information, visit endocrine.org/ENDO2021.

CLINICAL ENDOCRINOLOGY UPDATE (CEU) 2020 AND ENDOCRINE BOARD REVIEW (EBR) 2020
Given the global recommendations for social distancing, these historically live courses will transition to live online courses in 2020. We look forward to delivering the premier content that makes CEU and EBR so valuable. For updates, please visit endocrine.org/CEU2020 and endocrine.org/EBR2020.
IMPROVING OUTCOMES IN ACROMEGALY: Let Your Patients Be Your Guide

Monday, June 8, 2020
12:00 PM – 1:30 PM EDT

AGENDA

12:00 PM  Introduction and Pretest
Adriana Ioachimescu, MD, PhD

12:10 PM  Acromegaly Pathophysiology and Personalized Measures of Manifestations
Shlomo Melmed, MD

12:30 PM  Acromegaly: Current and Emerging Treatment Paradigms
Lisa Nachtigall, MD

12:55 PM  Clinical Cases
Moderated by
Adriana Ioachimescu, MD, PhD

1:15 PM  Posttest and Question & Answer

1:30 PM  Conclusion

ACTIVITY CHAIR

Adriana Ioachimescu, MD, PhD
Professor of Medicine (Endocrinology) and Neurosurgery
Emory University School of Medicine
Co-Director, Emory Pituitary Center
Atlanta, GA

FACULTY

Shlomo Melmed, MD
Executive Vice President and Dean
Cedars-Sinai Medical Center
Los Angeles, CA

Lisa Nachtigall, MD
Clinical Director
Neuroendocrine and Pituitary Clinical Center
Massachusetts General Hospital
Associate Professor
Department of Medicine
Harvard Medical School
Boston, MA

REGISTRATION
To register for ENDO Online 2020 and/or add an Ancillary program to your existing ENDO Online 2020 registration, visit the ENDO registration page.

This continuing medical education activity is provided by Educational Partner This activity is supported by an educational grant from Chiasma, Inc.
LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 8–12

Use the schedule provided below to organize the sessions you will attend during Endo Online 2020.

**MONDAY, JUNE 8**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00–10:05 AM</td>
<td>WELCOME</td>
</tr>
<tr>
<td></td>
<td>E. Dale Abel, MD, PhD, Immediate Past President, Endocrine Society</td>
</tr>
</tbody>
</table>
| 10:05–11:00 AM| THE IMPACT OF COVID-19 ON ENDOCRINOLOGY  
1.0 AMA PRA Category 1 Credits™  
Chairs: Andrea Giustina, MD and John Newell-Price, MD, PhD, FRCP  
Impact of Diabetes/Obesity on Adverse Outcomes from COVID-19  
Manuel Puig-Domingo, MD, PhD  
Practical Management of Diabetes in Patients with COVID-19  
Daniel J. Drucker, MD  
Clinical Guidance for Patients with Adrenal Insufficiency During COVID-19 Pandemic  
Wiebke Arlt, MD, DSc, FRCP, FMedSci  
Panel Discussion with Faculty  
Drs. Arlt, Drucker, Giustina, Newell-Price, and Puig-Domingo |
| 12:00–1:30 PM | IMPROVING OUTCOMES IN ACROMEGALY: LET PATIENTS BE YOUR GUIDE  
1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points  
Supported by Chiasma, Inc.  
Managed by Vindico Medical Education  
Chair: Adriana Ioachimescu, MD, PhD  
Acromegaly Pathophysiology and Personalized Measures of Manifestations  
Shlomo Melmed, MD  
Acromegaly: Current and Emerging Treatment Paradigms  
Lisa Nachtigall, MD  
Clinical Cases  
Adriana Ioachimescu, MD, PhD |

**TUESDAY, JUNE 9: BASIC SCIENCE DAY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:00–11:00 AM| BASIC MECHANISMS IN REPRODUCTION: FROM BEGINNING TO END  
1.0 AMA PRA Category 1 Credits™  
Chair: Genevieve Scott Neal-Perry, PhD, MD  
Regulation of Mouse Uterine Contractility by Regulator of G-Protein Signalling 2  
Daniela Urrugo, BHSc  
Kisspeptin as a Biomarker for Pregnancy Complications  
Maria Phylactou, MBBS  
Ovarian Follicle Survival Is Determined by Follicle-Stimulating Hormone Receptor (FSHR) and Estrogen Receptor (GPER) Heteromers  
Livio Casarini, PhD  
The Expression of the Homeodomain Transcription Factor SIX3 within Kisspeptin Neurons Is Necessary for Reproduction in Mice  
Shanna Newton Lavalle, BS |
LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 8–12 (CONTINUED)

11:00 AM–12:00 PM
THE MANY FACES OF DIABETES, OBESITY, AND METABOLISM
1.0 AMA PRA Category 1 Credits™
Chair: Kevin Y Lee, PhD
Circadian Regulation of Chromatin State Mediates Pancreatic Islet Incretin Response
Benjamin John Weidemann, BS
Hepatocyte Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Offsets the Anti-Steatogenic Effects of Thiazolidinediones in Obese Male Mice
Jose T Muratalla, Biochemistry Undergrad
The Transcriptional Coactivation Function of EHMT2 Restricts Chronic Glucocorticoid Exposure Induced Insulin Resistance
Rebecca Arwyn Lee, MS
Epinephrine Is Essential for Normal Renal Glucose Reabsorption via the Glucose Transporter GLUT2
Arwa Mahmoud Elsheikh, MBBS

12:00–1:00 PM
KEYNOTE: IF WE KNEW THEN WHAT WE KNOW NOW, WOULD WE HAVE APPROACHED THE DEVELOPMENT OF ENDOCRINE THERAPIES DIFFERENTLY
1.0 AMA PRA Category 1 Credits™
Keynote Presenter: Donald P. McDonnell, PhD
Moderator: Stephen R. Hammes, MD, PhD

1:00–2:00 PM
THE MANY FACES OF NUCLEAR RECEPTOR BIOLOGY
1.0 AMA PRA Category 1 Credits™
Chair: Zeynep Madak-Erdogan, PhD
Kruppel-Like Factors 9 and 13 Cooperate to Maintain Mammalian Neuronal Differentiation
Jose Avila-Mendoza, PhD
Expression of SLC35F1 in the Plasma Membrane of Cells of Aldosterone Producing Cell Clusters (APCCs) and Its Possible Role in Aldosterone Synthesis
Emily Goodchild, BMBS, BSc
Nuclear Receptor CAR Protects Female Mice from the Development of Diet-Induced Nonalcoholic Fatty Liver Disease
Fabiana Oliviero, Masters Degree
When the Glucocorticoid Receptor Meets the Mineralocorticoid Receptor in the Nucleus of Human Cells
Maria G. Petrillo, PhD

2:00–3:00 PM
FROM THE BRAIN TO THE BELLY—INSIGHTS INTO PITUITARY AND ADRENAL PHYSIOLOGY
1.0 AMA PRA Category 1 Credits™
Chair: Lori Therese Raetzman, PhD
OTX2 Mutations in Congenital Hypopituitarism Patients
Louise Cheryl Gregory, PhD
Single-Cell Sequencing Identifies Novel Regulators of Thyrotrope Populations and POU1F1-Independent Thyroid-Stimulating Hormone Expression
Leonard Cheung, PhD
Glucocorticoid Production in the Nervous and Immune Systems: Evidence for a Local HPA Axis Homolog
Melody Salehzadeh, BSc
Sepsis-Induced Critical Illness in Mice Alters Key Regulators of ACTH Production and Secretion Within the Anterior Pituitary Gland
Arno Téblick, MD
BREAKING BAD:
REDUCING GLUCOSE VARIABILITY AND INCREASING TIME IN RANGE IN PATIENTS WITH DIABETES

WEDNESDAY, JUNE 10, 2020  12:00–1:30 PM EDT

LEARNING OBJECTIVES

Upon completing this activity, learners will be able to:

• Better understand risks related to hypoglycemia
• Decrease the frequency and severity of hypoglycemia as an ADE among patients with T2D on insulin and/or SUs who are identified as high risk
• Discuss the role of currently available pipeline methods to lower hypoglycemia risk

AGENDA

Welcome and Introduction
Steven Edelman, MD

Setting the Stage: The Science Behind Time in Range
Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD

Method to the Madness: How to Integrate Time in Range into Your Practice
Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD

Case Workshop
Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD

CME Credits: 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points
ENDOCRINE SOCIETY PRESENTS

BREAKING THE CYCLE:
APPROACHES TO LONG-TERM WEIGHT LOSS AND OBESITY CARE

THURSDAY, JUNE 11, 2020 12:00–1:30 PM EDT

PROGRAM CHAIR
W. Timothy Garvey, MD
Department Chair of Nutrition Science
University of Alabama
Birmingham, AL

FACULTY
Sangeeta R. Kashyap, MD
Assistant Professor of Medicine
Cleveland Clinic Foundation
Cleveland, Ohio

Lisa Neff, MD
Assistant Professor of Medicine
Northwestern University
Chicago, IL

LEARNING OBJECTIVES
Upon completing this activity, learners will be able to:
• Review and identify the available and emerging therapeutic approaches to obesity
• Know what’s new in the obesity medicine pipeline
• Review different approaches to weight loss/maintenance

AGENDA
Welcome and Introduction
W. Timothy Garvey, MD

Life Cycle of a Patient with Obesity Case Scenarios Featuring a Standardized Patient On:

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Provider</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle Therapy</td>
<td>Lisa Neff, MD</td>
</tr>
<tr>
<td>Medical Therapy</td>
<td>W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>Surgery</td>
<td>Sangeeta R. Kashyap, MD</td>
</tr>
</tbody>
</table>

Roundtable Discussion and Closing
All Faculty

CME Credits: 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points

This activity is supported by an educational grant from Novo Nordisk, Inc.
### WEDNESDAY, JUNE 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM–12:00 PM</td>
<td>EXHIBIT HALL HOURS</td>
</tr>
</tbody>
</table>
| 12:00–1:30 PM   | **BREAKING BAD: REDUCING GLUCOSE VARIABILITY AND INCREASING TIME IN RANGE IN PATIENTS WITH DIABETES**  
|                 | 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points              |
|                 | *Supported by Novo Nordisk, Inc., Abbott Diabetes Care, Medtronic*   |
|                 | *Chair: Steven Edelman, MD*                                          |
|                 | *Setting the Stage: The Science Behind Time in Range*                |
|                 | Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD             |
|                 | *Method to the Madness: How to Integrate Time in Range into Your Practice*|
|                 | Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD             |

### THURSDAY, JUNE 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM–12:00 PM</td>
<td>EXHIBIT HALL HOURS</td>
</tr>
</tbody>
</table>
| 12:00–1:30 PM   | **BREAKING THE CYCLE: APPROACHES TO LONG-TERM WEIGHT LOSS AND OBESITY CARE**  
|                 | 1.0 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points              |
|                 | *Supported by Novo Nordisk, Inc.*                                    |
|                 | *Chair: W. Timothy Garvey, MD*                                       |
|                 | *Life Cycle of a Patient with Obesity Case Scenarios Featuring a Standardized Patient On: Lifestyle Therapy* |
|                 | Lisa Neff, MD                                                        |
|                 | *Life Cycle of a Patient with Obesity Case Scenarios Featuring a Standardized Patient On: Medical Therapy*   |
|                 | W. Timothy Garvey, MD                                               |
|                 | *Life Cycle of a Patient with Obesity Case Scenarios Featuring a Standardized Patient On: Surgery*            |
|                 | Sangeeta R. Kashyap, MD                                             |

### FRIDAY, JUNE 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM–12:00 PM</td>
<td>EXHIBIT HALL HOURS</td>
</tr>
<tr>
<td>1:00–1:45 PM</td>
<td><strong>WHAT’S NEW WITH ABIM’S MAINTENANCE OF CERTIFICATION?</strong></td>
</tr>
<tr>
<td></td>
<td>0.75 AMA PRA Category 1 Credits™</td>
</tr>
<tr>
<td></td>
<td><em>Presenter: Susan J. Mandel, MD, MPH</em></td>
</tr>
<tr>
<td></td>
<td><em>Moderator: Florence D. Mickens, MPA, JD</em></td>
</tr>
</tbody>
</table>
Tuesday, June 9
Basic Science Day

10:00–11:00 AM  BASIC MECHANISMS IN REPRODUCTION: FROM BEGINNING TO END
1.0 AMA PRA Category 1 Credits™
Chair: Genevieve Scott Neal-Perry, PhD, MD
Regulation of Mouse Uterine Contractility by Regulator of G-Protein Signalling 2
Daniela Urrego, BHSsc
Kisspeptin as a Biomarker for Pregnancy Complications
Maria Phylactou, MBBS
Ovarian Follicle Survival Is Determined by Follicle-Stimulating Hormone Receptor (FSHR)
and Estrogen Receptor (GPER) Heteromers
Livio Casarini, PhD
The Expression of the Homeodomain Transcription Factor SIX3 within Kisspeptin
Neurons Is Necessary for Reproduction in Mice
Shanna Newton Lavalle, BS

11:00 AM–12:00 PM  THE MANY FACES OF DIABETES, OBESITY, AND METABOLISM
1.0 AMA PRA Category 1 Credits™
Chair: Kevin Y Lee, PhD
Circadian Regulation of Chromatin State Mediates Pancreatic Islet Incretin Response
Benjamin John Weidemann, BS
Hepatocyte Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Offsets the
Anti-Steatogenic Effects of Thiazolidinediones in Obese Male Mice
Jose T Muratalla, Biochemistry Undergrad
The Transcriptional Coactivation Function of EHMT2 Restricts Chronic Glucocorticoid
Exposure Induced Insulin Resistance
Rebecca Arwyn Lee, MS
Epinephrine Is Essential for Normal Renal Glucose Reabsorption via the Glucose
Transporter GLUT2
Arwa Mahmoud Elsheikh, MBBS

12:00–1:00 PM  KEYNOTE: IF WE KNEW THEN WHAT WE KNOW NOW, WOULD WE HAVE
APPROACHED THE DEVELOPMENT OF ENDOCRINE THERAPIES DIFFERENTLY
1.0 AMA PRA Category 1 Credits™
Keynote Presenter: Donald P. McDonnell, PhD
Moderator: Stephen R. Hammes, MD, PhD
1:00–2:00 PM
THE MANY FACES OF NUCLEAR RECEPTOR BIOLOGY
1.0 AMA PRA Category 1 Credits™
Chair: Zeynep Madak-Erdogan, PhD
Kruppel-Like Factors 9 and 13 Cooperate to Maintain Mammalian Neuronal Differentiation
Jose Avila-Mendoza, PhD
Expression of SLC35F1 in the Plasma Membrane of Cells of Aldosterone Producing Cell Clusters (APCCs) and Its Possible Role in Aldosterone Synthesis
Emily Goodchild, BMBS, BSc
Nuclear Receptor CAR Protects Female Mice from the Development of Diet-Induced Nonalcoholic Fatty Liver Disease
Fabiana Oliviero, Master’s Degree
When the Glucocorticoid Receptor Meets the Mineralocorticoid Receptor in the Nucleus of Human Cells
Maria G. Petrillo, PhD

2:00–3:00 PM
FROM THE BRAIN TO THE BELLY—INSIGHTS INTO PITUITARY AND ADRENALEAR PHYSIOLOGY
1.0 AMA PRA Category 1 Credits™
Chair: Lori Therese Raetzman, PhD
OTX2 Mutations in Congenital Hypopituitarism Patients
Louise Cheryl Gregory, PhD
Single-Cell Sequencing Identifies Novel Regulators of Thyrotrope Populations and POU1F1-Independent Thyroid-Stimulating Hormone Expression
Leonard Cheung, PhD
Glucocorticoid Production in the Nervous and Immune Systems: Evidence for a Local HPA Axis Homolog
Melody Salehzadeh, BSc
Sepsis-Induced Critical Illness in Mice Alters Key Regulators of ACTH Production and Secretion Within the Anterior Pituitary Gland
Arno Téblick, MD
ACTIVITY OVERVIEW AND FORMAT
This highly engaging and interactive live symposium will answer participant questions regarding the management of patients with adult growth hormone disorder (aGHD). Faculty will participate in a combination of didactic presentations and roundtable discussions to address currently relevant topics regarding the treatment of aGHD. In addition, the audience will be able to ask questions based on their personal level of knowledge and clinical experience, and these questions will be addressed immediately and thoroughly from multiple expert viewpoints.

INTENDED AUDIENCE
This activity is intended for endocrinologists and endocrinology healthcare providers who diagnose and manage aGHD.

LEARNING OBJECTIVES
Upon completing this activity, learners will be able to:
• Identify aGHD based on presenting disease features and results of appropriate diagnostic tests
• Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics
• Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring
• Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood

PROGRAM AGENDA
12:00 – 12:10 PM  Program Introduction and Preactivity Assessment
12:10 – 12:25 PM  How Does aGHD Present and How Should the Diagnosis Be Confirmed?
12:25 – 12:45 PM  What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?
12:45 – 1:05 PM   What Techniques Can Provide Solutions to the Challenges of Treating aGHD?
1:05 – 1:25 PM    What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?
1:25 – 1:30 PM    Postactivity Assessment and Closing

FACULTY
MARK E MOLITCH, MD—PROGRAM CHAIR
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

DAVID R CLEMMONS, MD
University of North Carolina
Chapel Hill, North Carolina

JULIE SILVERSTEIN, MD
Medical Director Pituitary Center
Associate Professor of Medicine and Neurological Surgery
Division Endocrinology, Metabolism and Lipid Research
Washington University School of Medicine
St Louis, Missouri

REGISTRATION
There is no cost to participate in this symposium. Register for ENDO Online 2020 here. Add an Ancillary Symposium to your existing registration here.

CME CREDITS: 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points
LEARNING OBJECTIVES

Upon completing this activity, learners will be able to:

- Better understand risks related to hypoglycemia
- Decrease the frequency and severity of hypoglycemia as an ADE among patients with T2D on insulin and/or Sus who are identified as high risk
- Discuss the role of currently available pipeline methods to lower hypoglycemia risk

AGENDA

Welcome and Introduction
Lack of Hypoglycemia Awareness in Insulin and Sulfonylurea-Using Diabetics
Michael McDermott, MD

Review of Endocrine Society’s Prevention Initiative and Discussion of Management Strategies and Current Pipeline Methods to Lower Severe Hypoglycemia
Michael McDermott, MD

Master Clinician Discussions:
- Hypoglycemia Considerations and Management in Patients with CAD and CKD
  Elizabeth Seaquist, MD
- New Treatment Options for Severe Hypoglycemia
  Cecilia Low Wang, MD
- Severe Hypoglycemia Patient on Continuous Glucose Monitoring
  Michael McDermott, MD

Roundtable Discussion and Closing
All Faculty
### LIVE AND ANCILLARY SYMPOSIA

**SESSIONS: JUNE 15–19**

**USE THE SCHEDULE PROVIDED BELOW TO ORGANIZE THE SESSIONS YOU WILL ATTEND DURING ENDO ONLINE 2020.**

#### MONDAY, JUNE 15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM–12:00 PM</td>
<td>EXHIBIT HALL HOURS</td>
</tr>
</tbody>
</table>
| 12:00–1:30 PM  | BLAZING AHEAD WITH ADVANCES IN THE MANAGEMENT OF ADULT GROWTH HORMONE DISORDER  
1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points  
Supported by Novo Nordisk, Inc.  
Managed by Institute for Medical and Nursing Education  
Chair: Mark E Molitch, MD  
Speakers: David R Clemmons, MD and Julie Silverstein, MD  
How Does aGHD Present and How Should the Diagnosis Be Confirmed?  
What are the Treatment Options for Adults with GHD and the Consequences of Remaining Untreated?  
What Techniques Can Provide Solutions to the Challenges of Treating aGHD?  
What are the Unique aGHD Management Challenges as Pediatric Patients with GHD Transition to Adulthood? |

#### TUESDAY, JUNE 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM–12:00 PM</td>
<td>EXHIBIT HALL HOURS</td>
</tr>
</tbody>
</table>
| 12:00–1:00 PM  | WHAT ELSE YOU SHOULD KNOW ABOUT RESILIENCY, COMMUNICATIONS, COLLABORATIONS, AND TEACHING STRATEGIES: A LIVE QUESTION AND ANSWER SESSION WITH FACULTY  
1.0 AMA PRA Category 1 Credits™ |

#### WEDNESDAY, JUNE 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM–12:00 PM</td>
<td>EXHIBIT HALL HOURS</td>
</tr>
</tbody>
</table>
| 12:00–1:30 PM  | SEVERE HYPOGLYCEMIA: THE FREQUENTLY FORGOTTEN THREAT  
1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points  
Supported by Lilly USA, LLC  
Chair: Michael McDermott, MD  
Lack of Hypoglycemia Awareness in Insulin and Sulfonylurea-Using Diabetics  
Michael McDermott, MD  
Review of Endocrine Society’s Prevention Initiative and Discussion of Management Strategies and Current Pipeline Methods to Lower Severe Hypoglycemia  
Michael McDermott, MD  
Master Clinician Discussions:  
- Hypoglycemia Considerations and Management in Patients with CAD and CKD  
  Elizabeth Seaquist, MD  
- New Treatment Options for Severe Hypoglycemia  
  Cecilia Low Wang, MD  
- Severe Hypoglycemia Patient on Continuous Glucose Monitoring  
  Michael McDermott, MD |
### THURSDAY, JUNE 18

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12:00–1:00 PM | TYPE ONE DIABETES FELLOWS CONFERENCE QUESTIONS AND ANSWERS WITH THE FACULTY  
**1.0 AMA PRA Category 1 Credits™** |
| 1:00–1:30 PM | DEVICE DEMONSTRATION BY ABBOTT DIABETES CARE, INC.                     |
| 1:30–2:00 PM | DEVICE DEMONSTRATION BY INSULET CORPORATION                           |

### FRIDAY, JUNE 19

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00–12:30 PM</td>
<td>DEVICE DEMONSTRATION BY MEDTRONIC DIABETES</td>
</tr>
<tr>
<td>12:30–1:00 PM</td>
<td>DEVICE DEMONSTRATION BY DEXCOM, INC.</td>
</tr>
<tr>
<td>1:00–1:30 PM</td>
<td>DEVICE DEMONSTRATION BY TANDEM DIABETES CARE, INC.</td>
</tr>
</tbody>
</table>
**ON-DEMAND SESSIONS**

**ON-DEMAND SESSIONS WILL BE AVAILABLE FOR YOU TO VIEW AT YOUR CONVENIENCE STARTING ON MONDAY, JUNE 8 AT 11:00 AM FOLLOWING OUR OPENING SESSION, THE IMPACT OF COVID-19 ON ENDOCRINOLOGY.**

### PROFESSIONAL DEVELOPMENT SESSIONS

- **EFFECTIVE TEACHING STRATEGIES**
  1.0 AMA PRA Category 1 Credits™
  Nuha A. El Sayed, MD, MM Sc
  Mark S. Roberson, PhD

- **MANAGING COMMUNICATION CHALLENGES IN SCIENCE**
  1.0 AMA PRA Category 1 Credits™
  Sally Camper, PhD
  Cecilia Low Wang, MD
  Peter Trainer, MD

- **RESILIENCY AND MANAGING BURNOUT**
  1.0 AMA PRA Category 1 Credits™
  Stanley Andrisse, PhD
  Deborah T. Rana, MSc, MD, FAAP
  Stuart Slavin, MD, Med

- **TRANSCENDING BOUNDARIES: HOW TO EFFECTIVELY BUILD GLOBAL NETWORKS AND PARTNERSHIPS**
  1.0 AMA PRA Category 1 Credits™
  Diana Cruz Topete, PhD
  Ana Claudia Latronico, MD, PhD

### MEET THE PROFESSOR CLINICAL SESSIONS

- **CONTROVERSIES IN BARIATRIC SURGERY**
  0.75 AMA PRA Category 1 Credits™
  Jenny Tong MD, MPH
  Marzieh Salehi, MD

- **HEALTHCARE OF THE TRANSWOMAN ACROSS THE LIFESPAN**
  0.75 AMA PRA Category 1 Credits™
  Vin Tangpricha MD, PhD

- **MODERATE TO SEVERE ACTIVE THYROID EYE DISEASE**
  0.75 AMA PRA Category 1 Credits™
  Chrysoula Dosiou, MD
  Andrea Kossler, MD

- **PHARMACOTHERAPY IN OBESITY**
  0.75 AMA PRA Category 1 Credits™
  Marc-Andre Cornier, MD
  David Saxon, MD, MSc

- **TYPE 1 DIABETES MELLITUS: FROM PRECONCEPTION TO POSTPARTUM**
  0.75 AMA PRA Category 1 Credits™
  Elizabeth Buschur, MD
ON-DEMAND SESSIONS (CONTINUED)

EDUCATIONAL SESSIONS

- **BREAKING BARRIERS TO CARE**
  - 1.0 AMA PRA Category 1 Credits™
  - Increasing Patient Participation in Research: Strategies for Success
    James R. Gavin, PhD, MD
  - Reconsidering Race in the Estimation of Kidney Function
    Nwamaka D. Eneanya, MD, MPH

- **2020 ENDOCRINE FELLOWS SERIES: TYPE 1 DIABETES CARE AND MANAGEMENT***
  - 10.0 AMA PRA Category 1 Credits™ and 10.0 ABIM MOC Points
  - A Fresh Look at Insulin Therapy
  - Challenging Cases in the Diagnosis of T1D
  - Practical Considerations and Approaches to Data Management
    Irl B. Hirsch, MD
  - Developmental Considerations For Youth with T1D and Their Families
    Jill Weissberg-Benchell, PhD, CDE
  - Exercise Management: Considerations and Strategies for T1D
    Michael Riddell, PhD
  - Hypoglycemia in T1D: Risks and Practical Prevention Strategies
    Elizabeth Rachel Seaquist, MD
  - Identifying and Confronting Challenging Transitions
    Linda M. Siminerio, RN, PhD, CDE
  - Implementing Realistic Nutrition Strategies
    Alison Evert, MS, RD, CDE
  - Insights into Insulin Pump Therapy
  - The Endocrinologist's Role in Screening/Managing Microvascular Disease
    Janet B. McGill, MD
  - Interpreting CGM with Your Patients
    Davida F. Kruger, Masters
  - Managing the Sick Patient at Home
  - Optimizing Multiple Daily Injection Therapy
    Jenise Colleen Wong, MD, PhD
  - Time in Range: The Power of Partnership
    Kelly Close, MBA
  - Going Beyond Injected Insulin: Emerging Options for T1D
    David M. Harlan, MD, UMass Memorial Medical Center
  - T1D and the Prevention and Treatment of Macrovascular Disease
    Robert H. Eckel, MD, University of Colorado
  - What I Wish I was Told When I Left my Fellowship
    Luisa Duran, MD, John Muir Health

  *This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc.; Dexcom, Inc.; Helmsley Charitable Trust; Insulet Corporation; Lilly USA, LLC; Medtronic Diabetes; Novo Nordisk, Inc.; and Tandem Diabetes Care.

  *Please Note: The evaluation content is available on the Endocrine Society Center for Learning at education.endocrine.org.

- **TELEMEDICINE IN THE AGE OF COVID-19**
  - 1.0 AMA PRA Category 1 Credits™
  - Developed in collaboration with the European Society of Endocrinology
  - Chairs: Gary D. Hammer, MD and Martin Reincke, MD
  - Perspectives on Rare Endocrine Conditions
    Alberto M. Pereira Arias, MD, PhD
  - Lessons Learned from Virtual Tumor Boards
    Sophie Leboulleux, MD
  - New Use of Home Lab Measurements for e-consults
    Ravinder J. Singh, PhD
ON-DEMAND SESSIONS (CONTINUED)

PRIMARY PREVENTION OF ASCVD AND T2DM IN PATIENTS AT METABOLIC RISK: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE

1.5 AMA PRA Category 1 Credits™

Moderator: Marie E. McDonnell, MD
Task Force Chair: James L. Rosenzweig, MD
Panelists:
Lars F. Berglund, MD, PhD
Marie-France Hivert, MD
Rita R. Kalyani, MD

THE YEAR IN PITUITARY: CLINICAL AND RESEARCH BREAKTHROUGHS

0.75 AMA PRA Category 1 Credits™

Mirjam Christ-Crain, MD, PhD

JDRF: TYPE 1 DIABETES - LOOKING INTO THE FUTURE

1.5 AMA PRA Category 1 Credits™

Chair: Sanjoy Dutta, PhD
Cures 1: Endogenous Approach - Combining Beta Cell Regenerative and Immunotherapeutic Approaches for T1D
Carla Joy Greenbaum, MD
Cures 2: Exogenous Approach - Cell (Beta) Replacement Therapy for T1D
Bernhard Hering, MD
Innovations in Treatments: Device- and Drug-Based Approaches for Management of T1D
Lori M. Laffel, MD, MPH

CLINICAL TRIAL ABSTRACT PRESENTATIONS

ADRENAL MEDICINE – CLINICAL APPLICATIONS AND NEW THERAPIES

0.5 AMA PRA Category 1 Credits™

A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia
Deborah P. Merke, MS, MD
The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study
Richard Joseph Auchus, MD, PhD

CHALLENGES IN REPRODUCTIVE ENDOCRINOLOGY: LATE BREAKING INSIGHTS

0.25 AMA PRA Category 1 Credits™

Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay
Yee-Ming Chan, MD, PhD

CLINICAL CHALLENGES IN DIABETES AND METABOLISM

0.75 AMA PRA Category 1 Credits™

Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
Juan Pablo Frias, MD
Leptin Decreases De Novo Lipogenesis in Lipodystrophic Patients
Annah Petek Baykal, BS
Racial Differences in Technology Use Among Type 1 Diabetes in a Safety-Net Hospital
Kathryn Fantasia, MD

MECHANISMS AND TREATMENT OF OBESITY IN HUMANS

0.25 AMA PRA Category 1 Credits™

Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial
Aaron S. Kelly, PhD
NEW FRONTIERS IN BONE AND MINERAL METABOLISM
1.0 AMA PRA Category 1 Credits™

- Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
  Thomas O. Carpenter, MD
- Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
  Farzana Perwad, MD
- Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
  Robert A. Feldman, MD
- Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
  Anne Sophie Sølling, MD

THYROID AUTOIMMUNITY AND BENIGN THYROID DISEASE
0.25 AMA PRA Category 1 Credits™

- An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)
  Lori J. Wirth, MD

UNDERSTANDING PEDIATRIC GROWTH DISORDERS
0.5 AMA PRA Category 1 Credits™

- Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
  Aristides K. Maniatis, MD
- Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial
  Cheri L. Deal, MD, PhD
CELEBRATING 25 YEARS OF DIVERSITY IN ENDOCRINOLOGY

FOLLOW OUR JOURNEY TO CREATING A MORE DIVERSE AND INCLUSIVE GLOBAL ENDOCRINE COMMUNITY THROUGH THESE ENDOCRINE NEWS ARTICLES IN THE ENDO ONLINE 2020 RESOURCE CENTER:

A QUARTER CENTURY CELEBRATING DIVERSITY
A RAINBOW COALITION: LGBTQ+ OUTREACH
EXPANDING HORIZONS: A LOOK AT THE ENDOCRINE SOCIETY’S EVOLVING MINORITY OUTREACH
EMBRACING AUTHENTICITY: CELEBRATING 25 YEARS OF DIVERSITY AND INCLUSION
2020 LAUREATE AWARDS

FRED CONRAD KOCH LIFETIME ACHIEVEMENT AWARD
Presented to Richard J. Santen, MD

SIDNEY H. INGBAR AWARD FOR DISTINGUISHED SERVICE
Presented to Carol A. Lange, PhD

INTERNATIONAL EXCELLENCE IN ENDOCRINOLOGY AWARD
Presented to Roy Shires, MBBCl, PhD, FRCP

OUTSTANDING CLINICAL INVESTIGATOR AWARD
Presented to Greet H. Van den Berghe, MD, PhD

OUTSTANDING LEADERSHIP IN ENDOCRINOLOGY AWARD
Presented to John C. Marshall, MD, PhD

VIGERSKY OUTSTANDING CLINICAL PRACTITIONER AWARD
Presented to Peter A. Singer, MD

OUTSTANDING EDUCATOR AWARD
Presented to Alvin C. Powers, MD

RICHARD E. WEITZMAN OUTSTANDING EARLY CAREER INVESTIGATOR AWARD
Presented to Andrew N. Dauber, MD

OUTSTANDING MENTOR AWARD
Presented to Ashely Grossman, MD, FRCP

THE JOHN D. BAXTER PRIZE FOR ENTREPRENEURSHIP
Presented to Daniel J. Drucker, MD

GERALD D. AURBACH AWARD FOR OUTSTANDING TRANSLATIONAL RESEARCH
Presented to Donald P. McDonnell, PhD

OUTSTANDING INNOVATION AWARD
Presented to Christopher B. Newgard, PhD

OUTSTANDING SCHOLARLY PHYSICIAN AWARD
Presented to R. Michael Tuttle, MD

ROY O. GREEP AWARD FOR OUTSTANDING RESEARCH
Presented to Eleftheria Maratos-Flier, MD
PRODUCT THEATERS AND EXHIBIT HALL VIEWING

Product Theater Presentations and Exhibits offer ENDO Online 2020 learners additional educational opportunities. A number of companies will provide a 30-minute focused presentation on the latest products available on the market that clinicians and advanced practice professionals that can impact your practice. Additionally, through the virtual exhibit hall that you can continue your educational journey to learn more about products that can make a difference to your patients.

Thank you to this year’s exhibitors:

PRODUCT THEATERS

NP THYROID® (THYROID TABLETS, USP): UNDERSTANDING THE OPTIONS FOR MANAGEMENT OF HYPOTHYROIDISM

Sponsored by Acella Pharmaceuticals
Presenter:
Gary M. Pepper, MD
Palm Beach Diabetes & Endocrine Specialists
Palm Beach, FL

For the majority of patients seeking treatment for hypothyroidism and Hashimoto’s thyroiditis, levothyroxine (LT4) monotherapy is the recommended first line treatment. However, many patients remain symptomatic despite achieving normal lab values and thyroid function tests. There is a growing body of clinical evidence that suggests certain subsets of patients with hypothyroidism, such as those with genetic polymorphisms of the D2 deiodinase gene, may benefit from combination therapy with both T4 and T3. This product theater will provide a synopsis of the management of hypothyroidism with combination therapy as well as an overview of NP Thyroid, which is a natural desiccated porcine thyroid extract containing both T4 and T3 indicated for thyroid hormone replacement in hypothyroidism and Hashimoto’s thyroiditis.

THE NEXT GENERATION OF THE GUARDIAN™ CONNECT CONTINUOUS GLUCOSE MONITORING SYSTEM: ACCURACY WHEN IT MATTERS MOST WITH REAL WORLD OUTCOMES

Sponsored by Medtronic
Presenter:
Bruce Bode, MD

Introduction to the new Guardian™ Connect CGM app, featuring even more customizable prediction, easier onboarding, and a new CareLink™ reports for your practice. Please join us to learn more about the system and the different measures of accuracy, with real world outcomes and case studies demonstrating the integration of CareLink™ reports to help you manage your patients on multiple daily injections.

A PARADIGM SHIFT FOR THE MANAGEMENT OF THYROID EYE DISEASE (TED)

Sponsored by Horizon Therapeutics
Presenters:
Raymond S. Douglas, MD, PhD
Professor of Ophthalmology
Director, Orbital and Thyroid Eye Disease Center
Cedars-Sinai Medical Center, Los Angeles, CA
Terry J. Smith, MD
Frederick G.L. Huetwell
Professor of Ophthalmology and Visual Sciences
Professor, Department of Internal Medicine
Kellogg Eye Center
University of Michigan Medical School, Ann Arbor, MI

Come learn about the importance of early identification and a new treatment approach for Thyroid Eye Disease (TED) management. This presentation is intended for US-based healthcare professionals.

ENABLING TELEMEDICINE AND REMOTE MONITORING WITH THE FREESTYLE LIBRE 14 DAY SYSTEM

This program is sponsored by Abbott, the speaker or speakers are presenting on behalf of Abbott and the content of the program is in compliance with applicable regulatory requirements.

Presenter:
Daniel Einhorn, MD, FACP, FACE
Medical Director, Scripps Whittier Diabetes Institute
Clinical Professor of Medicine, University of California, San Diego
President, Diabetes and Endocrine Associates

Join us to learn about the #1 CGM worldwide† used by more than 2 million people*, the FreeStyle Libre 14 day system.

Daniel Einhorn, MD, FACP, FACE will share how he utilizes the FreeStyle Libre 14 day system to enable diabetes management and monitoring of patients remotely. He will also share real-world telemedicine patient cases.

Disclaimers
†Data based on the number of users worldwide for FreeStyle Libre personal CGM compared to the number of users for other leading personal CGM brands.

*Data based on the number of users worldwide for FreeStyle Libre products. In the United States product is branded FreeStyle Libre 14 day System.
More than 400 skeletal dysplasias have a genetic basis of disease identified. Currently, these patients may experience lifelong, progressive, multisystemic comorbidities. This on-demand presentation, moderated by Dr. Ron Rosenfeld, brings together 4 experts who will discuss the genetic basis of skeletal dysplasias, their pathophysiology, and the development of investigational therapies for achondroplasia.

FINALLY, AN ORAL TESTOSTERONE REPLACEMENT THERAPY FOR MEN WITH HYPOGONADISM
Sponsored by Clarus Therapeutics
Presenter: Paresh Dandona MD, PhD
State University of New York at Buffalo, Buffalo, New York
Join us for an overview of an FDA-approved and available oral testosterone replacement therapy. During this program, an expert will discuss the history and challenges of TRTs, and the pathway to approval for this oral option, as well as its safety and efficacy profiles.

PRODUCT THEATERS AND EXHIBIT HALL VIEWING (CONTINUED)

CLINICAL MANAGEMENT OF ADRENOCORTICAL CARCINOMA (ACC)
Sponsored by HRA Pharma Rare Diseases
Presenter: Mouhammed Amir Habra, MD, FACP, FACE
Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders
MD Anderson Cancer Center, Houston, TX
Adrenocortical Carcinoma (ACC) is a rare endocrine tumor with a poor prognosis that requires a multi-disciplinary approach between endocrinologists, oncologists and surgeons. The presentation will focus on the diagnosis, prognosis and current treatment guidelines for ACC patients.

PRECISION MEDICINE IN SKELETAL DYSPLASIAS: GENETICS, PATHOPHYSIOLOGY, & INVESTIGATIONAL APPROACHES TO THERAPY
Sponsored by BioMarin Pharmaceuticals
Chair and Presenter: Ron Rosenfeld, MD
Pediatric Endocrinologist
Professor and Chair (emeritus) of Pediatrics
Oregon Health and Science University
Presenters: Julie Hoover-Fong, MD, PhD
Clinical Geneticist
Greenberg Center for Skeletal Dysplasias
McKusick-Nathans Department of Genetic Medicine
Johns Hopkins University, Baltimore, MD
Nadia Merchant, MD
Pediatric Endocrinologist & Clinical Geneticist
Children’s National Hospital, Washington, DC
Bradley S. Miller, MD, PhD
Professor
Division of Endocrinology
Department of Pediatrics
University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
More than 400 skeletal dysplasias have a genetic basis of disease identified. Currently, these patients may experience lifelong, progressive, multisystemic comorbidities. This on-demand presentation, moderated by Dr. Ron Rosenfeld, brings together 4 experts who will discuss the genetic basis of skeletal dysplasias, their pathophysiology, and the development of investigational therapies for achondroplasia.

FINALLY, AN ORAL TESTOSTERONE REPLACEMENT THERAPY FOR MEN WITH HYPOGONADISM
Sponsored by Clarus Therapeutics
Presenter: Paresh Dandona MD, PhD
State University of New York at Buffalo, Buffalo, New York
Join us for an overview of an FDA-approved and available oral testosterone replacement therapy. During this program, an expert will discuss the history and challenges of TRTs, and the pathway to approval for this oral option, as well as its safety and efficacy profiles.

Product Theater presentations are not part of ENDO Online 2020 official educational programming as planned by the Endocrine Society Program Committee. These events are neither sponsored nor endorsed by the Endocrine Society. These events do not qualify for continuing medical education (CME) credit.
EXHIBITORS

A
Abbott Diabetes Care
Acella Pharmaceuticals
Amarin Pharma
Amgen
Amneal Pharmaceuticals, Inc.
Ascendis Pharma Inc.
AstraZeneca

B
BioMarin Pharmaceutical
Brain Recovery Project: Childhood Epilepsy Surgery Foundation

C
Clarus Therapeutics, Inc.
CoachCare
Crinetics Pharmaceuticals

D
Dexcom Inc.

E
EKF Diagnostics

H
Horizon Therapeutics
HRA Pharma

I
Immunovant, Inc.
Insulet Corporation
IPSEN Biopharmaceuticals, Inc.

M
Medtronic

N
National Adrenal Diseases Foundation
Norland at Swissray
Novo Nordisk Diabetes Care
Novo Nordisk Healthcare AG

P
Pfizer Inc.
Progenics

R
Roche Diabetes Care, Inc.

T
Takeda Pharmaceutical Company Limited

U
Ultradynyx Pharmaceutical, Inc. - Commercial Booth
Ultradynyx Pharmaceuticals, Inc. - Medical Booth
HIGHLIGHTS OF ENDONLINE2020
INCLUDING PRESENTATIONS SCHEDULED FOR ENDO 2020
FOCUS ON DIABETES & COMORBIDITIES

www.endohighlights2020.com:
• Video introduction
• International faculty interviews
• Virtual meeting presentations
• Expert overview on the latest scientific information presented
• ENDO 2020 conference summaries from key oral presentations
• Podcasts from poster sessions
• Downloadable slide kit

Keep up with the latest advances in diabetology & endocrinology care from the convenience of your home and office! Visit www.endohighlights2020.com!

AVAILABLE IN 4 LANGUAGES!

SCAN THE CODE WITH YOUR SMARTPHONE

THIS PROGRAM IS DEVELOPED BY THE ENDOCRINE SOCIETY IN COLLABORATION WITH INFOMEDICA AND SUPPORTED BY AN INDEPENDENT EDUCATIONAL GRANT PROVIDED BY NOVO NORDISK A/S. THE NATURE OF THE PROGRAM IS PURELY EDUCATIONAL AND NOVO NORDISK A/S HAS NO INFLUENCE IN THE CONTENT PRESENTED.
To get a preview of some of the research that was to be presented at ENDO, view the ENDO 2020 abstracts which are now available online in a supplemental issue of JES: bit.ly/ENDO2020Abstracts

© 2020 ENDOCRINE SOCIETY